Is Dow Inc. (DOW) a Top Value Stock in 2023?

NYSE: DOW | Dow Inc. News, Ratings, and Charts

DOW – PE of 6.6 + 5% dividend yield is a pretty good equation for an attractive stock. And that is the equation for Dow Incorporated (DOW) at this time. Find out why it is one of our favorite value stocks in 2023 in the article below…

The answer to the headline is YES!…Dow Inc (DOW) is one of the most attractive value stocks for the year ahead.

Why?

Let me spell it out for you now…

As you know, DOW is a diversified chemical manufacturing company combining science and technology to develop innovative solutions that are essential to human progress. It’s well diversified portfolio includes Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.

This selection is in many ways the antithesis of the previous top value pick, Bristol-Myers Squibb (BMY) which was quite conservative. Here we are selecting a leading materials company to enjoy tremendous growth as the economy gets back on track later in 2023. Likely those good times continue for another 5-10 years just like the previous bullish cycle pushing EPS and share price higher.

An interesting part of the DOW story is their surprisingly low-cost structure that has allowed the company to withstand inflationary pressures better than most companies. It’s also in a position to pass on price increases given that its products are essential for so many industries. This combination points to healthy profit margins ahead.

The company has a Value Grade of A, which certainly makes sense with a P/E of only 6.6. It also has a Quality Grade of B which points to superior operational efficiency.

If that was not attractive enough, the company also provides tremendous income thanks to a 5% dividend yield. As rates start to come down later in 2023 it will make income stocks like DOW all the more attractive boosting its already impressive upside potential.

Want to Discover More Value Stocks?

DOW is just 1 of 7 attractive value stocks found in a new special report we just put together. Click the link below to claim your free copy now:

7 SEVERELY Undervalued Stocks

What To Do Next?

Watch my brand new presentation: “2023 Stock Market Outlook” covering:

  • Why 2023 is a “Jekyll & Hyde” year for stocks
  • 5 Warnings Signs the Bear Returns in Early 2023
  • 8 Trades to Profit on the Way Down
  • Plan to Bottom Fish @ Market Bottom
  • 2 Trades with 100%+ Upside Potential as New Bull Emerges
  • And Much More!

Watch Now: “2023 Stock Market Outlook” > 

Wishing you a world of investment success!


Steve Reitmeister…but everyone calls me Reity (pronounced “Righty”)
CEO, Stock News Network and Editor, Reitmeister Total Return

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


DOW shares were trading at $56.01 per share on Thursday morning, down $0.83 (-1.46%). Year-to-date, DOW has gained 11.15%, versus a 1.53% rise in the benchmark S&P 500 index during the same period.


About the Author: Steve Reitmeister


Steve is better known to the StockNews audience as “Reity”. Not only is he the CEO of the firm, but he also shares his 40 years of investment experience in the Reitmeister Total Return portfolio. Learn more about Reity’s background, along with links to his most recent articles and stock picks. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
DOWGet RatingGet RatingGet Rating
.INXGet RatingGet RatingGet Rating
DIAGet RatingGet RatingGet Rating
SPYGet RatingGet RatingGet Rating
QQQGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Stock Market Expert Predicts 3-6 Months of Pain

2 important market developments are leading market expert Steve Reitmeister to predict 3 to 6 months of painful market conditions pushing the S&P 500 (SPY) lower. Read on for the full story...

3 Pharmaceutical Stocks Addressing Global Health Challenges

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more...

3 Tech Stocks Analysts Say Are "Strong Buys" for 2025

The technology industry is well-positioned for significant growth thanks to the rapid advancements in emerging technologies and the digitization of business operations. Amid this backdrop, fundamentally solid tech stocks Adobe (ADBE), Leidos Holdings (LDOS), and DocuSign (DOCU) could be strong buys for 2025. Continue reading...

3 Tech Stocks Under $20 With Breakout Potential

The tech sector is the core of innovation, from transforming industries to powering economic progress. Amid this backdrop, investors could consider buying sound under $20 tech stocks Vimeo (VMEO), PubMatic (PUBM), and Eventbrite (EB). Keep reading…

How Bad Will 2025 Be for Stocks?

As January goes...so goes the stock market. And right now that saying bodes poorly for the year ahead. Especially for the S&P 500 (SPY). That is why Steve Reitmeister shares 2 different paths the market could take in 2025 and how to get your portfolio on the right side of the action.

Read More Stories

More Dow Inc. (DOW) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All DOW News